Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER SCREENING

Liquid biopsy versus tumor biopsy for clinical-trial recruitment

Nature Medicine volume 26, pages 1815–1816 (2020)Cite this article

Subjects

Studies demonstrate the efficacy of screening by liquid biopsy for enrollment in clinical trials of precision cancer therapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Corcoran, R. B. & Chabner, B. A. N. Engl. J. Med. 379, 1754–1765 (2018).

    Article  CAS  Google Scholar 

  2. Siravegna, G. et al. Ann. Oncology 30, 1580–1590 (2019).

    Article  CAS  Google Scholar 

  3. Tie, J. et al. Sci. Transl. Med. 8, 346ra392 (2016).

    Article  Google Scholar 

  4. Kurtz, D. M. et al. J. Clin. Oncol. 36, 2845–2853 (2018).

    Article  CAS  Google Scholar 

  5. Parikh, A. R. et al. Clin. Cancer Res. 26, 1877–1885 (2020).

    Article  CAS  Google Scholar 

  6. Reinert, T. et al. JAMA Oncol. 5, 1124–1131 (2019).

    Article  Google Scholar 

  7. Lennon, A. M. et al. Science 369, eabb960 (2020).

    Article  Google Scholar 

  8. Liu, M. C. et al. Ann. Oncol. 31, 745–759 (2020).

    Article  Google Scholar 

  9. Nakamura, Y. et al. Nat. Med. https://doi.org/10.1038/s41591-020-1063-5 (2020).

  10. Turner, N. C. et al. Lancet Oncol. 21, 1296–1308 (2020).

    Article  CAS  Google Scholar 

  11. Leighl, N. B. et al. Clin. Cancer Res. 25, 4691–4700 (2019).

    Article  CAS  Google Scholar 

  12. Parikh, A. R. et al. Nat. Med. 25, 1415–1421 (2019).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA

    Ryan B. Corcoran

Authors
  1. Ryan B. Corcoran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryan B. Corcoran.

Ethics declarations

Competing interests

R.B.C. has received consulting or speaking fees from Abbvie, Amgen, Array Biopharma/Pfizer, Asana Biosciences, Astex Pharmaceuticals, AstraZeneca, Avidity Biosciences, BMS, C4 Therapeutics, Chugai, Elicio, Fog Pharma, Fount Therapeutics/Kinnate Biopharma, Genentech, Guardant Health, Ipsen, LOXO, Merrimack, Mirati Therapeutics, Natera, N-of-one/Qiagen, Novartis, nRichDx, Revolution Medicines, Roche, Roivant, Shionogi, Shire, Spectrum Pharmaceuticals, Symphogen, Tango Therapeutics, Taiho, Warp Drive Bio, Zikani Therapeutics; holds equity in Avidity Biosciences, C4 Therapeutics, Fount Therapeutics/Kinnate Biopharma, nRichDx and Revolution Medicines; and has received research funding from Asana, AstraZeneca, Lilly and Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Corcoran, R.B. Liquid biopsy versus tumor biopsy for clinical-trial recruitment. Nat Med 26, 1815–1816 (2020). https://doi.org/10.1038/s41591-020-01169-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-020-01169-6

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer